# Clinical Trials Data BRAF - Document 37

# Expanded Access Program With Nivolumab to Treat Melanoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT02142218

"eligibilityCriteria": "For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n\* ECOG Performance Status of 0-1\n\* Histologically confirmed malignant melanoma\n\* Progressed on or after treatment with an anti-CTLA4\n\nExclusion Criteria:\n\n\* Active brain metastases\n\* Life Expectancy \\<6 weeks\n\* Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy\n\* Subjects with autoimmune disease",  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no mention of specific exclusion or inclusion criteria related to a BRAF gene mutation. The criteria listed include performance status, histological confirmation of melanoma, previous treatments, brain metastases, life expectancy, previous therapies, and autoimmune diseases. Therefore, based on this information alone, a BRAF gene mutation does not directly affect eligibility for the trial. However, it's always important for patients to confirm with the trial coordinators or healthcare professionals, as there may be additional considerations or trial updates not specified in this section.